Scientific exchange

What is scientific exchange?

Scientific exchange is the non-promotional sharing and discussion of scientific evidence, clinical data, medical knowledge and professional insights between a life sciences company and external stakeholders. It is transparent, balanced and grounded in appropriate sources, with the aim of supporting education, clinical understanding and informed decision-making rather than encouraging product use.

It may take place through a Medical science liaison, publications, congress presentations, scientific meetings or one-to-one conversations. Exchange is often two-way: healthcare professionals receive relevant information, while the company learns about evidence gaps, clinical experience and unmet needs.

Why does scientific exchange matter in medical affairs?

Scientific exchange is a core responsibility of Medical affairs. It helps teams build scientific credibility, maintain stakeholder trust and ensure that external discussions reflect the available evidence, including its limitations and uncertainties.

It also gives medical teams a structured way to understand questions arising in clinical practice. Recurring themes can inform medical strategy, educational priorities and future research, provided that insights are documented and assessed rather than treated as isolated comments. Regulatory, ethical and company requirements must be followed throughout.

How is scientific exchange run and assessed in practice?

The precise process depends on the channel, audience and local requirements, but it commonly includes:

• Defining the scientific objective, intended audience and appropriate format.
• Selecting current, relevant evidence and checking its place within the evidence hierarchy.
• Preparing or approving materials through the required medical, legal, regulatory or compliance process.
• Training medical colleagues to explain the evidence accurately and handle questions within their role.
• Presenting benefits, risks, limitations and areas of uncertainty in a fair and understandable way.
• Using the correct process for unsolicited questions, including requests about unapproved products or uses where applicable.
• Recording interactions appropriately and routing adverse events, product complaints or other reportable information through established procedures.
• Capturing recurring questions and observations for review without identifying individual patients unnecessarily.

Assessment should consider the quality and relevance of the exchange, not simply activity volumes. Useful indicators include whether stakeholder questions were answered, evidence gaps were identified, follow-up was completed and insights led to an appropriate medical action.

What does good scientific exchange look like?

Good exchange is accurate, current, relevant to the stakeholder and clear about what the evidence can and cannot show. Claims should be traceable to their sources, conflicting findings should not be hidden, and uncertainty should be stated plainly. The level of technical detail should suit the audience without oversimplifying the science.

It should also be responsive rather than scripted. Medical colleagues need enough subject knowledge to explore the stakeholder’s question, distinguish evidence from interpretation and acknowledge when further review is required. A high number of meetings does not compensate for selective presentation, weak follow-up or poor documentation.

Who owns scientific exchange, and where do teams go wrong?

Medical affairs usually owns the scientific standards, governance and delivery model, while field medical teams often conduct the exchange. Publications, evidence, regulatory, safety and compliance colleagues may contribute according to the subject and company process. Clear responsibilities are particularly important at congresses and cross-functional meetings where medical and commercial activity may occur alongside each other.

Common problems include treating exchange as a one-way presentation, using promotional language, overstating preliminary findings, relying on outdated materials or collecting observations without a defined medical insight capture process. Another failure is allowing commercial objectives to determine the scientific conclusion rather than keeping medical judgement independent.

How is scientific exchange different from related medical activities?

Scientific exchange is the broader, ongoing communication of evidence and medical knowledge. An advisory board is a defined forum for obtaining expert advice; insight capture is the structured recording and analysis of what stakeholders communicate; and an evidence generation programme produces new data to address prioritised gaps. Publications and congress presentations are channels through which exchange occurs, rather than synonyms for the exchange itself.

It also differs from promotional communication. Promotion is intended to support the appropriate use of an authorised product within applicable rules, whereas scientific exchange is non-promotional and focused on scientific understanding. The practical boundary depends on the content, context, audience, speaker and local requirements, so teams need clear governance rather than relying on the channel name alone.